PL1799633T3 - Krystaliczne postacie chlorowodorku (-)-(1R,2R)-3-(3-dimetyloamino-1-etylo-2-metylopropylo)-fenolu do stosowania jako składnik aktywny w kompozycjach farmaceutycznych - Google Patents

Krystaliczne postacie chlorowodorku (-)-(1R,2R)-3-(3-dimetyloamino-1-etylo-2-metylopropylo)-fenolu do stosowania jako składnik aktywny w kompozycjach farmaceutycznych

Info

Publication number: PL1799633T3
Authority: PL; Poland
Prior art keywords: methylpropyl; dimethylamino; ethyl; active ingredient; pharmaceutical compositions
Prior art date: 2004-06-28

Application number

PL05770026T

Other languages

English (en)

Inventor

Andreas Fischer

Helmut Buschmann

Michael Gruss

Dagmar Lischke

Original Assignee

Gruenenthal Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-06-28

Filing date

2005-06-27

Publication date

2011-06-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34925507&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1799633(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-06-27 Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh

2011-06-30 Publication of PL1799633T3 publication Critical patent/PL1799633T3/pl

Links

ZELFLGGRLLOERW-YECZQDJWSA-N 3-[(2r,3r)-1-(dimethylamino)-2-methylpentan-3-yl]phenol;hydrochloride Chemical compound Cl.CN(C)C[C@H](C)[C@@H](CC)C1=CC=CC(O)=C1 ZELFLGGRLLOERW-YECZQDJWSA-N 0.000 title 1
239000004480 active ingredient Substances 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
- C07C215/54—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
- C07C217/62—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C213/10—Separation; Purification; Stabilisation; Use of additives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Pain & Pain Management (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Hematology (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

PL05770026T 2004-06-28 2005-06-27 Krystaliczne postacie chlorowodorku (-)-(1R,2R)-3-(3-dimetyloamino-1-etylo-2-metylopropylo)-fenolu do stosowania jako składnik aktywny w kompozycjach farmaceutycznych PL1799633T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP04015091A EP1612203B1 (en)	2004-06-28	2004-06-28	Crystalline forms of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride
PCT/EP2005/006884 WO2006000441A2 (en)	2004-06-28	2005-06-27	Crystalline forms of (-)-(1r,2r)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride
EP05770026A EP1799633B1 (en)	2004-06-28	2005-06-27	Crystalline forms of (-)-(1r,2r)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride for use as active ingredient in pharmaceutical compositions

Publications (1)

Publication Number	Publication Date
PL1799633T3 true PL1799633T3 (pl)	2011-06-30

Family

ID=34925507

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL04015091T PL1612203T3 (pl)	2004-06-28	2004-06-28	Krystaliczne postacie chlorowodorku (-)-(1R,2R)-3-(3-dimetyloamino-1-etylo-2-metylo-propylo)fenolu
PL05770026T PL1799633T3 (pl)	2004-06-28	2005-06-27	Krystaliczne postacie chlorowodorku (-)-(1R,2R)-3-(3-dimetyloamino-1-etylo-2-metylopropylo)-fenolu do stosowania jako składnik aktywny w kompozycjach farmaceutycznych

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PL04015091T PL1612203T3 (pl)	2004-06-28	2004-06-28	Krystaliczne postacie chlorowodorku (-)-(1R,2R)-3-(3-dimetyloamino-1-etylo-2-metylo-propylo)fenolu

Country Status (27)

Country	Link
US (16)	US20070213405A1 (pl)
EP (2)	EP1612203B1 (pl)
JP (1)	JP4990764B2 (pl)
KR (1)	KR101096501B1 (pl)
CN (1)	CN1997621B (pl)
AR (2)	AR049949A1 (pl)
AT (2)	ATE368639T1 (pl)
AU (1)	AU2005256512B2 (pl)
BR (2)	BR122018014454B8 (pl)
CA (1)	CA2572147C (pl)
CY (2)	CY1106929T1 (pl)
DE (2)	DE602004007905T2 (pl)
DK (2)	DK1612203T3 (pl)
EC (1)	ECSP17046065A (pl)
ES (2)	ES2291780T3 (pl)
HR (1)	HRP20110050T8 (pl)
IL (1)	IL180373A (pl)
MX (1)	MXPA06014741A (pl)
NO (3)	NO338605B1 (pl)
NZ (1)	NZ551605A (pl)
PE (1)	PE20060372A1 (pl)
PL (2)	PL1612203T3 (pl)
PT (2)	PT1612203E (pl)
RU (1)	RU2423345C2 (pl)
SI (2)	SI1612203T1 (pl)
WO (1)	WO2006000441A2 (pl)
ZA (1)	ZA200700774B (pl)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7776314B2 (en)	2002-06-17	2010-08-17	Grunenthal Gmbh	Abuse-proofed dosage system
US20070048228A1 (en)	2003-08-06	2007-03-01	Elisabeth Arkenau-Maric	Abuse-proofed dosage form
DE10336400A1 (de)	2003-08-06	2005-03-24	Grünenthal GmbH	Gegen Missbrauch gesicherte Darreichungsform
DE102005005446A1 (de)	2005-02-04	2006-08-10	Grünenthal GmbH	Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10361596A1 (de)	2003-12-24	2005-09-29	Grünenthal GmbH	Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DK1612203T3 (da) *	2004-06-28	2007-12-03	Gruenenthal Gmbh	Krystallinske former af (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenolhydrochlorid
DE102004032049A1 (de)	2004-07-01	2006-01-19	Grünenthal GmbH	Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de)	2005-02-04	2006-08-10	Grünenthal GmbH	Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102007011485A1 (de)	2007-03-07	2008-09-11	Grünenthal GmbH	Darreichungsform mit erschwertem Missbrauch
DE102007019417A1 (de) *	2007-04-23	2008-11-13	Grünenthal GmbH	Tapentadol zur Schmerzbehandlung bei Arthrose
CN101939287B (zh) *	2007-12-07	2014-10-22	格吕伦塔尔有限公司	(1r,2r)-3-(3-二甲基氨基-1-乙基-2-甲基-丙基)-苯酚的结晶变体
CA2713128C (en)	2008-01-25	2016-04-05	Gruenenthal Gmbh	Pharmaceutical dosage form
BRPI0912014A2 (pt)	2008-05-09	2019-03-06	Grünenthal GmbH	processo para a preparação de uma formulação em pó intermediária e uma forma de dosagem sólida final sob uso de uma etapa de congelamento por atomização
US20100272815A1 (en) *	2009-04-28	2010-10-28	Actavis Group Ptc Ehf	Amorphous form of tapentadol hydrochloride
RU2015138422A (ru)	2009-07-22	2018-12-25	Грюненталь Гмбх	Стабильная при окислении, прочная на излом лекарственная форма
CN102573805A (zh)	2009-07-22	2012-07-11	格吕伦塔尔有限公司	热熔挤出的控制释放剂型
US8288592B2 (en) *	2009-09-22	2012-10-16	Actavis Group Ptc Ehf	Solid state forms of tapentadol salts
WO2011138037A2 (de)	2010-05-05	2011-11-10	Ratiopharm Gmbh	Festes tapentadol in nicht-kristalliner form
ES2860676T3 (es) *	2010-07-23	2021-10-05	Gruenenthal Gmbh	Sales o cocristales de 3- (3-dimetilamino-1-etil-2-metil-propil) -fenol
BR112013005234A2 (pt)	2010-09-02	2016-05-03	Gruenenthal Gmbh	forma de dosagem resistente à violação compreendendo um polímero aniônico.
NZ607392A (en)	2010-09-02	2015-03-27	Gruenenthal Chemie	Tamper resistant dosage form comprising inorganic salt
WO2012051246A1 (en)	2010-10-12	2012-04-19	Ratiopharm Gmbh	Tapentadol hydrobromide and crystalline forms thereof
MX369121B (es)	2011-03-04	2019-10-30	Gruenenthal Gmbh	Formulacion farmaceutica acuosa de tapentadol para administracion oral.
US9446008B2 (en)	2011-03-04	2016-09-20	Gruenenthal Gmbh	Semisolid aqueous pharmaceutical composition containing tapentadol
MX348831B (es) *	2011-03-04	2017-06-30	Gruenenthal Gmbh	Administración parenteral de tapentadol.
PE20141638A1 (es)	2011-07-29	2014-11-22	Gruenenthal Chemie	Tableta a prueba de manipulacion que proporciona liberacion de farmaco inmediato
RS56527B1 (sr)	2011-07-29	2018-02-28	Gruenenthal Gmbh	Tableta za trenutno oslobađanje leka rezistentna na zloupotrebu
WO2013111161A2 (en) *	2012-01-10	2013-08-01	Msn Laboratories Limited	Process for the preparation of 3-aryl-2-methyl-propanamine derivatives and polymorphs thereof
WO2013120466A1 (en)	2012-02-17	2013-08-22	Zentiva, K.S.	A new solid form of tapentadol and a method of its preparation
MX356421B (es)	2012-02-28	2018-05-29	Gruenenthal Gmbh	Forma de dosificacion resistente a la manipulacion indebida que comprende un compuesto farmacologicamente activo y un polimero anionico.
DK2838512T3 (en)	2012-04-18	2018-11-19	Gruenenthal Gmbh	MANIPULATED AND DOSAGE DUMPED PHARMACEUTICAL DOSAGE FORM
US10064945B2 (en)	2012-05-11	2018-09-04	Gruenenthal Gmbh	Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
CZ304576B6 (cs) *	2012-07-24	2014-07-16	Zentiva, K.S.	Oxalát TAPENTADOLU a způsob jeho přípravy
CN102924303B (zh) *	2012-10-31	2013-11-20	合肥市新星医药化工有限公司	盐酸他喷他多晶型c及其制备方法和应用
JP6445537B2 (ja)	2013-05-29	2018-12-26	グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング	１個または複数の粒子を含有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形
AR096439A1 (es)	2013-05-29	2015-12-30	Gruenenthal Gmbh	Forma de dosificación resistente al uso indebido que contiene una o más partículas
EP2808319A1 (en)	2013-05-31	2014-12-03	Arevipharma GmbH	3-[3-(Dimethylamino)-1-ethyl-2-methylpropyl]phenol resin complex
US10624862B2 (en)	2013-07-12	2020-04-21	Grünenthal GmbH	Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
EP2845625A1 (en) *	2013-09-04	2015-03-11	Grünenthal GmbH	Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome
USD730877S1 (en)	2013-09-06	2015-06-02	Plantronics, Inc.	Communications headset
US9599565B1 (en) *	2013-10-02	2017-03-21	Ondax, Inc.	Identification and analysis of materials and molecular structures
WO2015071248A1 (en)	2013-11-15	2015-05-21	Synthon B.V.	Abuse-proofed extended release pharmaceutical composition comprising tapentadol
AU2014356581C1 (en)	2013-11-26	2020-05-28	Grunenthal Gmbh	Preparation of a powdery pharmaceutical composition by means of cryo-milling
CZ307492B6 (cs)	2014-02-04	2018-10-17	Zentiva, K.S.	Pevná forma maleátu tapentadolu a způsob její přípravy
GB2523089A (en) *	2014-02-12	2015-08-19	Azad Pharmaceutical Ingredients Ag	Stable polymorph form B of tapentadol hydrochloride
MX2016014738A (es)	2014-05-12	2017-03-06	Gruenenthal Gmbh	Formulacion en capsula de liberacion inmediata resistente a alteraciones que comprende tapentadol.
MX2016015417A (es)	2014-05-26	2017-02-22	Gruenenthal Gmbh	Multiparticulas protegidas contra vertido de dosis etanolico.
TW201642843A (zh)	2015-03-27	2016-12-16	歌林達有限公司	他噴他多腸胃外給藥的穩定製劑
JP2018517676A (ja)	2015-04-24	2018-07-05	グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング	即時放出および溶媒抽出に対する耐性を有する改変防止製剤
AU2016319203A1 (en)	2015-09-10	2018-02-22	Grünenthal GmbH	Protecting oral overdose with abuse deterrent immediate release formulations
PT3445742T (pt)	2016-04-19	2020-02-19	Ratiopharm Gmbh	Fosfato de tapentadol cristalino
EP3515412B1 (en)	2016-09-23	2025-04-23	Grünenthal GmbH	Stable formulation for parenteral administration of tapentadol
EP3585370A1 (en)	2017-02-23	2020-01-01	Grünenthal GmbH	Tapentadol as local anesthetic
CA3196954A1 (en)	2020-11-03	2022-05-12	Josep Bassaganya-Riera	Crystalline forms of piperazine-1,4-diylbis((6-(1h-benzoi[d]imidazo-2-yl)pyridin-2yl)methanone) as lancl2 modulators

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4426245A1 (de)	1994-07-23	1996-02-22	Gruenenthal Gmbh	1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
SI9720059B (sl) *	1996-08-14	2011-11-30	Searle & Co	Kristalinična oblika 4-/5-metil-3-fenilizoksazol-4-il/benzensulfonamida
AU1234002A (en) *	2000-10-31	2002-05-15	Ciba Sc Holding Ag	Crystalline forms of venlafaxine hydrochloride
US20050176790A1 (en)	2001-02-28	2005-08-11	Johannes Bartholomaus	Pharmaceutical salts
HUP0401694A3 (en) *	2001-09-13	2008-03-28	Kissei Pharmaceutical	Crystal forms of a hydrochloride salt of a hydroxynorephedrine derivative, pharmaceutical compositions comprising thereof and use
PE20030527A1 (es)	2001-10-24	2003-07-26	Gruenenthal Chemie	Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
DK1612203T3 (da) *	2004-06-28	2007-12-03	Gruenenthal Gmbh	Krystallinske former af (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenolhydrochlorid
CN101939287B (zh) *	2007-12-07	2014-10-22	格吕伦塔尔有限公司	(1r,2r)-3-(3-二甲基氨基-1-乙基-2-甲基-丙基)-苯酚的结晶变体

2004
- 2004-06-28 DK DK04015091T patent/DK1612203T3/da active
- 2004-06-28 SI SI200430461T patent/SI1612203T1/sl unknown
- 2004-06-28 ES ES04015091T patent/ES2291780T3/es not_active Expired - Lifetime
- 2004-06-28 AT AT04015091T patent/ATE368639T1/de active
- 2004-06-28 PL PL04015091T patent/PL1612203T3/pl unknown
- 2004-06-28 DE DE602004007905T patent/DE602004007905T2/de not_active Expired - Lifetime
- 2004-06-28 PT PT04015091T patent/PT1612203E/pt unknown
- 2004-06-28 EP EP04015091A patent/EP1612203B1/en not_active Expired - Lifetime
2005
- 2005-06-27 BR BR122018014454A patent/BR122018014454B8/pt active IP Right Grant
- 2005-06-27 RU RU2007103297/04A patent/RU2423345C2/ru active
- 2005-06-27 CA CA2572147A patent/CA2572147C/en not_active Expired - Lifetime
- 2005-06-27 MX MXPA06014741A patent/MXPA06014741A/es active IP Right Grant
- 2005-06-27 BR BRPI0512792-0A patent/BRPI0512792A/pt not_active Application Discontinuation
- 2005-06-27 DE DE602005026031T patent/DE602005026031D1/de not_active Expired - Lifetime
- 2005-06-27 SI SI200531252T patent/SI1799633T1/sl unknown
- 2005-06-27 PL PL05770026T patent/PL1799633T3/pl unknown
- 2005-06-27 WO PCT/EP2005/006884 patent/WO2006000441A2/en not_active Ceased
- 2005-06-27 KR KR1020077002099A patent/KR101096501B1/ko not_active Expired - Lifetime
- 2005-06-27 NZ NZ551605A patent/NZ551605A/en not_active IP Right Cessation
- 2005-06-27 ES ES05770026T patent/ES2359504T3/es not_active Expired - Lifetime
- 2005-06-27 JP JP2007518520A patent/JP4990764B2/ja not_active Expired - Lifetime
- 2005-06-27 AU AU2005256512A patent/AU2005256512B2/en not_active Expired
- 2005-06-27 EP EP05770026A patent/EP1799633B1/en not_active Expired - Lifetime
- 2005-06-27 PT PT05770026T patent/PT1799633E/pt unknown
- 2005-06-27 PE PE2005000742A patent/PE20060372A1/es active IP Right Grant
- 2005-06-27 AT AT05770026T patent/ATE496021T1/de active
- 2005-06-27 CN CN2005800216611A patent/CN1997621B/zh not_active Expired - Fee Related
- 2005-06-27 HR HR20110050T patent/HRP20110050T8/xx unknown
- 2005-06-27 DK DK05770026.2T patent/DK1799633T3/da active
- 2005-06-28 AR ARP050102663A patent/AR049949A1/es not_active Application Discontinuation
2006
- 2006-12-26 IL IL180373A patent/IL180373A/en active IP Right Grant
- 2006-12-28 US US11/646,232 patent/US20070213405A1/en not_active Abandoned
2007
- 2007-01-09 NO NO20070162A patent/NO338605B1/no unknown
- 2007-01-26 ZA ZA200700774A patent/ZA200700774B/xx unknown
- 2007-10-11 CY CY20071101312T patent/CY1106929T1/el unknown
2008
- 2008-11-20 US US12/274,747 patent/US20090186947A1/en not_active Abandoned
2009
- 2009-12-10 US US12/634,777 patent/US7994364B2/en not_active Expired - Lifetime
2011
- 2011-02-16 CY CY20111100192T patent/CY1111530T1/el unknown
- 2011-06-29 US US13/172,009 patent/US20110294898A1/en not_active Abandoned
2012
- 2012-08-03 US US13/565,867 patent/US20120302643A1/en not_active Abandoned
2013
- 2013-06-21 US US13/923,891 patent/US20140011886A1/en not_active Abandoned
2014
- 2014-06-13 US US14/304,313 patent/US20140296346A1/en not_active Abandoned
2015
- 2015-11-02 US US14/930,337 patent/US20160122287A1/en not_active Abandoned
2016
- 2016-05-30 NO NO20160914A patent/NO341239B1/no unknown
2017
- 2017-02-09 US US15/428,613 patent/US20170166515A1/en not_active Abandoned
- 2017-07-04 NO NO20171103A patent/NO343922B1/no unknown
- 2017-07-17 EC ECIEPI201746065A patent/ECSP17046065A/es unknown
- 2017-10-05 US US15/725,967 patent/US20180029976A1/en not_active Abandoned
2018
- 2018-04-12 US US15/951,838 patent/US20180230082A1/en not_active Abandoned
- 2018-10-26 US US16/172,100 patent/US20190062263A1/en not_active Abandoned
2019
- 2019-09-02 AR ARP190102495A patent/AR116052A2/es not_active Application Discontinuation
- 2019-10-14 US US16/600,884 patent/US20200102261A1/en not_active Abandoned
2020
- 2020-06-23 US US16/909,123 patent/US20200385334A1/en not_active Abandoned
2021
- 2021-03-08 US US17/194,717 patent/US20210261492A1/en not_active Abandoned
2023
- 2023-01-30 US US18/103,410 patent/US20230174458A1/en not_active Abandoned

Also Published As

Publication number	Publication date
PT1612203E (pt)	2007-08-20
US20180029976A1 (en)	2018-02-01
ECSP17046065A (es)	2018-11-30
BR122018014454B8 (pt)	2021-07-27
ES2359504T3 (es)	2011-05-24
AR049949A1 (es)	2006-09-20
EP1612203A1 (en)	2006-01-04
US20110294898A1 (en)	2011-12-01
US7994364B2 (en)	2011-08-09
EP1612203B1 (en)	2007-08-01
ZA200700774B (en)	2008-09-25
US20120302643A1 (en)	2012-11-29
PE20060372A1 (es)	2006-05-08
US20070213405A1 (en)	2007-09-13
ATE496021T1 (de)	2011-02-15
WO2006000441A2 (en)	2006-01-05
US20140296346A1 (en)	2014-10-02
US20230174458A1 (en)	2023-06-08
NO20171103A1 (no)	2007-01-24
MXPA06014741A (es)	2007-02-12
WO2006000441A3 (en)	2006-05-04
US20140011886A1 (en)	2014-01-09
PT1799633E (pt)	2011-03-07
US20210261492A1 (en)	2021-08-26
DE602004007905T2 (de)	2008-05-08
NO338605B1 (no)	2016-09-12
KR101096501B1 (ko)	2011-12-20
NZ551605A (en)	2010-01-29
JP4990764B2 (ja)	2012-08-01
US20090186947A1 (en)	2009-07-23
RU2423345C2 (ru)	2011-07-10
RU2007103297A (ru)	2008-08-10
NO341239B1 (no)	2017-09-25
PL1612203T3 (pl)	2007-12-31
CY1111530T1 (el)	2015-08-05
US20160122287A1 (en)	2016-05-05
ES2291780T3 (es)	2008-03-01
IL180373A0 (en)	2007-06-03
US20100160447A1 (en)	2010-06-24
CN1997621A (zh)	2007-07-11
NO343922B1 (no)	2019-07-08
US20190062263A1 (en)	2019-02-28
KR20070039929A (ko)	2007-04-13
JP2008504326A (ja)	2008-02-14
US20170166515A1 (en)	2017-06-15
BR122018014454B1 (pt)	2019-09-03
DK1799633T3 (da)	2011-03-28
EP1799633B1 (en)	2011-01-19
IL180373A (en)	2012-05-31
CN1997621B (zh)	2011-06-15
CY1106929T1 (el)	2012-09-26
CA2572147A1 (en)	2006-01-05
SI1799633T1 (sl)	2011-05-31
NO20160914A1 (no)	2007-01-24
HRP20110050T8 (en)	2011-03-31
EP1799633A2 (en)	2007-06-27
BRPI0512792A (pt)	2008-04-08
SI1612203T1 (sl)	2007-12-31
DK1612203T3 (da)	2007-12-03
CA2572147C (en)	2012-10-30
US20200385334A1 (en)	2020-12-10
AR116052A2 (es)	2021-03-25
US20180230082A1 (en)	2018-08-16
US20200102261A1 (en)	2020-04-02
AU2005256512A1 (en)	2006-01-05
NO20070162L (no)	2007-01-24
AU2005256512B2 (en)	2011-05-19
ATE368639T1 (de)	2007-08-15
HRP20110050T1 (hr)	2011-02-28
DE602005026031D1 (de)	2011-03-03
DE602004007905D1 (de)	2007-09-13

Publication	Publication Date	Title
SI1799633T1 (sl)	2011-05-31	Kristalinične oblike hidroklorida (-)-(1R,2R)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenola za uporabo kot aktivna sestavina v farmacevtskih sestavkih
DK1786403T3 (da)	2013-08-19	Mod misbrug sikret, oral indgivelsesform indeholdende (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
TWI366460B (en)	2012-06-21	Cannabinoid active pharmaceutical ingredient for improved dosage forms
ZA200705750B (en)	2008-11-26	Compositions and methods for stabilizing active pharmaceutical ingredients
PL2054411T3 (pl)	2015-02-27	Nowe związki, ich izomery lub ich farmaceutycznie dopuszczalne sole jako antagoniści receptora waniloidowego oraz zawierające je kompozycje farmaceutyczne
JO2973B1 (en)	2016-03-15	Fumarate salt for (alpha-beta-R) -6-bromo-alpha-[2- (methylamino) ethyl-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinoline ethanol
MY159203A (en)	2016-12-30	Solid preparation comprising alogliptin and metformin hydrochloride
IL206197A (en)	2015-03-31	Crystalline forms of the compound (r1, r2) –3– (3– dimethylamino – 1 – ethyl – 2 – methyl-profile) –phenol processes for their preparation, pharmaceutical compositions containing them, and their use in the preparation of pain treatment compositions
WO2007002597A3 (en)	2009-04-23	Modified-release formulations of a bupropion salt
HUE039142T2 (hu)	2018-12-28	Fungicid hatóanyag-kombinációk
EP2279732A3 (en)	2012-04-25	Compounds and compositions for delivering active agents
ZA200709788B (en)	2008-08-27	Cannabinold active pharmaceutical ingredient for Improved dosage forms
WO2007102127A3 (en)	2008-04-03	New amines
EP1861358A4 (en)	2011-08-31	NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANAGONIST, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
SI1932522T1 (sl)	2012-08-31	Terapevtsko sredstvo za jetrno bolezen, ki vsebuje 2-amino-1,3- propandiolni derivat kot aktivno sestavino
IL177402A0 (en)	2006-12-10	Composition for oral administration of tamsulosin hydrochloride
WO2007099410A3 (en)	2008-04-17	Formulations of fispemifene
WO2007035718A3 (en)	2009-06-18	Crystalline forms of the di-sodium salt of n-(5-chlorosalicyloyl)-8-aminocaprylic acid
WO2007083096A3 (en)	2007-11-01	N- (2, 3-difluorophenyl) -2- [4- ( {7-methoxy-5- [ (2r) -piperidin. -2-ylmethoxy] quinazoli n-4-yl}amino) -lh-pyrazol-1-yl] acetamide and n- (2, 3 -d i fluoro phenyl) -2- [4- ( {7-ethoxy-5- [ (2r) -piperidin. -2-ylmethoxy] quinazolin
WO2005121074A3 (en)	2006-05-18	Processes for the preparation of sertraline hydrochloride
WO2007022532A3 (en)	2009-04-23	Cyclopropyl compounds and compositions for delivering active agents
HK1116670A (en)	2009-01-02	Compositions and methods for stabilizing active pharmaceutical ingredients
MX2010002358A (es)	2010-03-22	Formulacion farmaceutica para liberacion prolongada.